Market cap
$1,272 Mln
Recently Viewed
Clear AllMarket cap
$1,272 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-88 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.1
Debt to Equity
0
Book Value
$--
EPS
$-16.2
Face value
--
Shares outstanding
43,764,300
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CinCor Pharma Inc (CINC)
| 136.5 | 0.1 | 136.5 | 27.4 | -- | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CinCor Pharma Inc (CINC)
|
29.1 | 1,271.8 | 0.0 | -88.1 | -- | -21.1 | -- | 1.0 |
| 3.9 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 | |
| 19.4 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 13.9 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.4 | 2,154.2 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.7 | |
| 16.6 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 3.8 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 17.2 | 445.5 | 4.8 | 53.5 | -- | 12.2 | 10.8 | 1.2 | |
| 22.6 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of... hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc.. Read more
CEO & Director
Mr. Marc M. P. de Garidel
CEO & Director
Mr. Marc M. P. de Garidel
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of CinCor Pharma Inc (CINC) is $29.06 (NASDAQ) as of 03-Mar-2023 09:30 EDT. CinCor Pharma Inc (CINC) has given a return of 27.4% in the last 1 years.
Since, TTM earnings of CinCor Pharma Inc (CINC) is negative, P/E ratio is not available.
The P/B ratio of CinCor Pharma Inc (CINC) is 1.02 times as on 03-Mar-2023, a 82 discount to its peers’ median range of 5.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of CinCor Pharma Inc (CINC) are Rs -- and Rs -- as of 24-Apr-2026.
CinCor Pharma Inc (CINC) has a market capitalisation of $ 1,272 Mln as on 03-Mar-2023. As per SEBI classification, it is a company.
Before investing in CinCor Pharma Inc (CINC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.